Literature DB >> 21479313

Combination approaches to potentiate immune response after photodynamic therapy for cancer.

Tyler G St Denis1, Kanza Aziz, Anam A Waheed, Ying-Ying Huang, Sulbha K Sharma, Pawel Mroz, Michael R Hamblin.   

Abstract

Photodynamic therapy (PDT) has been used as a cancer therapy for forty years but has not advanced to a mainstream cancer treatment. Although it has been shown to be an efficient way to destroy local tumors by a combination of non-toxic dyes and harmless visible light, it is its additional effects in mediating the stimulation of the host immune system that gives PDT great potential to become more widely used. Although the stimulation of tumor-specific cytotoxic T-cells that can destroy distant tumor deposits after PDT has been reported in some animal models, it remains the exception rather than the rule. This realization has prompted several investigators to test various combination approaches that could potentiate the immune recognition of tumor antigens that have been released after PDT. This review will cover these combination approaches using immunostimulants including various microbial preparations that activate Toll-like receptors and other receptors for pathogen-associated molecular patterns, cytokines growth factors, and approaches that target regulatory T-cells. We believe that by understanding the methods employed by tumors to evade immune response and neutralizing them, more precise ways of potentiating PDT-induced immunity can be devised.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21479313      PMCID: PMC3449163          DOI: 10.1039/c0pp00326c

Source DB:  PubMed          Journal:  Photochem Photobiol Sci        ISSN: 1474-905X            Impact factor:   3.982


  71 in total

1.  Tumor-specific T-lymphocyte cytotoxicity enhanced by low dose of C. parvum.

Authors:  B H Lau; R M Wang-Cheng; J Tosk
Journal:  J Leukoc Biol       Date:  1987-05       Impact factor: 4.962

2.  A defect in inducible beta-galactosidase of B lymphocytes in the osteopetrotic (mi/mi) mouse.

Authors:  N Yamamoto; V R Naraparaju
Journal:  Immunology       Date:  1996-08       Impact factor: 7.397

3.  Evidence for an important role of neutrophils in the efficacy of photodynamic therapy in vivo.

Authors:  W J de Vree; M C Essers; H S de Bruijn; W M Star; J F Koster; W Sluiter
Journal:  Cancer Res       Date:  1996-07-01       Impact factor: 12.701

4.  Macrophage-directed immunotherapy as adjuvant to photodynamic therapy of cancer.

Authors:  M Korbelik; V R Naraparaju; N Yamamoto
Journal:  Br J Cancer       Date:  1997       Impact factor: 7.640

Review 5.  Combination of photodynamic therapy with anti-cancer agents.

Authors:  M-F Zuluaga; N Lange
Journal:  Curr Med Chem       Date:  2008       Impact factor: 4.530

Review 6.  Photodynamic therapy for localized infections--state of the art.

Authors:  Tianhong Dai; Ying-Ying Huang; Michael R Hamblin
Journal:  Photodiagnosis Photodyn Ther       Date:  2009 Sep-Dec       Impact factor: 3.631

7.  Clinical and immunologic results of a phase II trial of sequential imiquimod and photodynamic therapy for vulval intraepithelial neoplasia.

Authors:  Ursula Winters; Sai Daayana; John T Lear; Anne E Tomlinson; Eyad Elkord; Peter L Stern; Henry C Kitchener
Journal:  Clin Cancer Res       Date:  2008-08-15       Impact factor: 12.531

8.  Immunotherapy of an experimental adenocarcinoma of the prostate.

Authors:  A Morales; J C Nickel; J Downey; J Clark; I van der Linden
Journal:  J Urol       Date:  1995-05       Impact factor: 7.450

9.  Uptake of the components of hematoporphyrin derivative by cells and tumours.

Authors:  J Moan; S Sommer
Journal:  Cancer Lett       Date:  1983-12       Impact factor: 8.679

10.  In vivo priming of two distinct antitumor effector populations: the role of MHC class I expression.

Authors:  H I Levitsky; A Lazenby; R J Hayashi; D M Pardoll
Journal:  J Exp Med       Date:  1994-04-01       Impact factor: 14.307

View more
  15 in total

1.  T-cell mediated anti-tumor immunity after photodynamic therapy: why does it not always work and how can we improve it?

Authors:  Florian Anzengruber; Pinar Avci; Lucas Freitas de Freitas; Michael R Hamblin
Journal:  Photochem Photobiol Sci       Date:  2015-06-11       Impact factor: 3.982

2.  RGD-Modified Albumin Nanoconjugates for Targeted Delivery of a Porphyrin Photosensitizer.

Authors:  Fang Li; Yan Zhao; Chengqiong Mao; Yi Kong; Xin Ming
Journal:  Mol Pharm       Date:  2017-07-25       Impact factor: 4.939

3.  CpG oligodeoxynucleotide as immune adjuvant enhances photodynamic therapy response in murine metastatic breast cancer.

Authors:  Yumin Xia; Gaurav K Gupta; Ana P Castano; Pawel Mroz; Pinar Avci; Michael R Hamblin
Journal:  J Biophotonics       Date:  2013-08-07       Impact factor: 3.207

4.  Cellular and vascular effects of the photodynamic agent temocene are modulated by the delivery vehicle.

Authors:  María García-Díaz; Masayoshi Kawakubo; Pawel Mroz; M Lluïsa Sagristà; Margarita Mora; Santi Nonell; Michael R Hamblin
Journal:  J Control Release       Date:  2012-07-27       Impact factor: 9.776

Review 5.  Photodynamic therapy induces an immune response against a bacterial pathogen.

Authors:  Ying-Ying Huang; Masamitsu Tanaka; Daniela Vecchio; Maria Garcia-Diaz; Julie Chang; Yuji Morimoto; Michael R Hamblin
Journal:  Expert Rev Clin Immunol       Date:  2012-07       Impact factor: 4.473

6.  Immune stimulating photoactive hybrid nanoparticles for metastatic breast cancer.

Authors:  Sean Marrache; Joshua H Choi; Smanla Tundup; Dhillon Zaver; Donald A Harn; Shanta Dhar
Journal:  Integr Biol (Camb)       Date:  2013-01       Impact factor: 2.192

Review 7.  Therapy of human papillomavirus-related disease.

Authors:  Peter L Stern; Sjoerd H van der Burg; Ian N Hampson; Thomas R Broker; Alison Fiander; Charles J Lacey; Henry C Kitchener; Mark H Einstein
Journal:  Vaccine       Date:  2012-11-20       Impact factor: 3.641

Review 8.  Oncologic Photodynamic Therapy: Basic Principles, Current Clinical Status and Future Directions.

Authors:  Demian van Straten; Vida Mashayekhi; Henriette S de Bruijn; Sabrina Oliveira; Dominic J Robinson
Journal:  Cancers (Basel)       Date:  2017-02-18       Impact factor: 6.639

9.  Calreticulin as cancer treatment adjuvant: combination with photodynamic therapy and photodynamic therapy-generated vaccines.

Authors:  Mladen Korbelik; Judit Banáth; Kyi Min Saw; Wei Zhang; Evaldas Čiplys
Journal:  Front Oncol       Date:  2015-02-03       Impact factor: 6.244

10.  Efficient photodynamic therapy on human retinoblastoma cell lines.

Authors:  Jan Walther; Stanislas Schastak; Sladjana Dukic-Stefanovic; Peter Wiedemann; Jochen Neuhaus; Thomas Claudepierre
Journal:  PLoS One       Date:  2014-01-31       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.